Related Experiment Video
Updated: Jul 26, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Pathway-level multi-omics analysis of the molecular mechanisms underlying the toxicity of long-term tacrolimus
Nguyen Thi Hai Yen1, Nguyen Ky Phat1, Jung-Hwa Oh2
1Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan 47392, Republic of Korea.
Abstract:
Tacrolimus (TAC)-based treatment is associated with nephrotoxicity and hepatotoxicity; however, the underlying molecular mechanisms responsible for this toxicity have not been fully explored. This study elucidated the molecular processes underlying the toxic effects of TAC using an integrative omics approach. Rats were sacrificed after 4 weeks of daily oral TAC administration at a dose of 5 mg/kg. The liver and kidney underwent genome-wide gene expression profiling and untargeted metabolomics assays. Molecular alterations were identified using individual data profiling modalities and further characterized by pathway-level transcriptomics-metabolomics integration analysis. Metabolic disturbances were mainly related to an imbalance in oxidant-antioxidant status, as well as in lipid and amino acid metabolism in the liver and kidney. Gene expression profiles also indicated profound molecular alterations, including in genes associated with a dysregulated immune response, proinflammatory signals, and programmed cell death in the liver and kidney. Joint-pathway analysis indicated that the toxicity of TAC was associated with DNA synthesis disruption, oxidative stress, and cell membrane permeabilization, as well as lipid and glucose metabolism. In conclusion, our pathway-level integration of transcriptome and metabolome and conventional analyses of individual omics profiles, provided a more comprehensive picture of the molecular changes resulting from TAC toxicity. This study also serves as a valuable resource for subsequent investigations aiming to understand the mechanism underlying the molecular toxicology of TAC.
Insights
Tacrolimus (TAC) causes kidney and liver damage through molecular disruptions. This study reveals TAC toxicity involves oxidative stress, altered metabolism, and cell death pathways, offering insights into its mechanisms.
Area of Science:
- Toxicology
- Molecular Biology
- Pharmacology
Background:
- Tacrolimus (TAC) is crucial for preventing organ transplant rejection but is linked to nephrotoxicity and hepatotoxicity.
- The precise molecular mechanisms driving TAC-induced organ damage remain incompletely understood.
Purpose of the Study:
- To elucidate the molecular pathways underlying Tacrolimus (TAC) toxicity in the liver and kidney.
- To utilize an integrative omics approach combining transcriptomics and metabolomics for a comprehensive analysis.
Main Methods:
- Rats received daily oral Tacrolimus (TAC) at 5 mg/kg for 4 weeks.
- Genome-wide gene expression profiling and untargeted metabolomics were performed on liver and kidney tissues.
- Data were analyzed individually and integrated using pathway-level transcriptomics-metabolomics analysis.
Main Results:
- Metabolic disturbances included imbalances in oxidant-antioxidant status, lipid, and amino acid metabolism.
- Gene expression changes indicated immune dysregulation, inflammation, and programmed cell death.
- Integrated analysis linked TAC toxicity to disrupted DNA synthesis, oxidative stress, cell membrane permeabilization, and altered lipid/glucose metabolism.
Conclusions:
- Integrative omics analysis provides a comprehensive understanding of TAC's molecular toxicology.
- Findings highlight oxidative stress, metabolic dysregulation, and cell death as key mechanisms in TAC-induced organ damage.
- This study serves as a foundation for future research into TAC toxicity mechanisms.
More Related Videos
00:05A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019